Table 3 |
||||||
|
Agreement table of diagnostic groups' basis on VPS |
||||||
|
VPSCAT(O1T1) |
VPSCAT(O2T1) |
VPSCAT(O3T1) |
||||
|
≥ 55% |
<55% |
≥ 55% |
<55% |
≥ 55% |
<55% |
|
|
|
||||||
|
SH |
14 (93.3%) |
1 (6.7%) |
21(95.5%) |
1 (4.5%) |
22 (91.7%) |
2 (8.3%) |
|
CH |
10 (62.5%) |
6 (37.5%) |
2 (18.2%) |
9 (81.8%) |
1 (7.7%) |
12 (92.3%) |
|
AH |
2 (13.3%) |
13 (89.7%) |
2 (15.4%) |
11 (84.6%) |
2 (14.3%) |
12 (85.7%) |
|
WDA |
0 (0%) |
9 (100%) |
0 (0%) |
8 (100%) |
0 (0%) |
3 (100%) |
|
Total |
26 (47.3%) |
29 (52.7%) |
25 (46.3%) |
29 (53.7%) |
25 (46.3%) |
29 (53.7%) |
|
|
||||||
|
SH: Simple Hyperplasia, CH: Complex Hyperplasia, AH: Atypical Hyperplasia, WDA: Well Differentiated Adenocarcinoma. |
||||||
|
Izadi-Mood et al. Diagnostic Pathology 2009 4:10 doi:10.1186/1746-1596-4-10 |
||||||
